A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey

Novartis

Status: Completed

Conditions: Myelofibrosis

Study type: Observational

Funder types: Industry

Identifiers

NCT07357441

CINC424ATR01

Details and patient eligibility

About

This was a non-interventional retrospective study. Data from patients who were diagnosed with myelofibrosis (MF) (primary MF, post-polycythemia vera MF & post-essential thrombocythemia MF) and treated with ruxolitinib for at least 3 months collectively were collected. The baseline visit was the visit that the patient started ruxolitinib treatment. Data was collected between January 01, 2015 and December 31, 2022. The main baseline clinical and laboratory data of the cohort with at least 3 months of ruxolitinib treatment was documented in order to identify real life patient data in Turkey.

All the data was transferred to a clinical report form (CRF), then to the Statistical Package for the Social Sciences (SPSS) software in an anonymous fashion. The source documents were secured for quality control of the data. The quality control of the data was controlled by an unbiased data entry coordinator.

Enrollment: 355 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with MF
• Treated with ruxolitinib for at least 3 months

Exclusion criteria

None identified.

Trial design

355 participants in 2 patient groups

Ruxolitinib Group 1

Description:

Patients diagnosed with intermediate-1 risk MF according to the Dynamic International Prognostic Scoring System Plus (DIPSS+) at the initial visit who were treated with ruxolitinib.

Ruxolitinib Group 2

Description:

Patients diagnosed with intermediate-2 and High risk MF according to the DIPSS+ at the initial visit who were treated with ruxolitinib.